You are here: Industry Insights > Biogen

News List

EU nod for new formulation of Biogen's Tysabri pharmatimes
April 13, 2021
European regulators have approved Biogen's application to market a subcutaneous (SC) injection of Tysabri (natalizumab) to treat relapsing-remitting multiple sclerosis (MS).
Biogen and Bio-Thera enter licencing agreement for arthritis biosimilar pharmaceutical-technology
April 12, 2021
Biogen and Bio-Thera Solutions have entered an agreement to develop, manufacture and commercialise the anti-interleukin-6 (IL-6) receptor monoclonal antibody BAT1806.
Psychiatry Consortium funds project investigating new schizophrenia treatments pharmatimes
January 26, 2021
The international Psychiatry Consortium has funded its first project – a partnership which will investigate a new drug target for the treatment of schizophrenia.
Samsung Bioepis Opens New Headquarters contractpharma
January 26, 2021
The 52,000-square-foot campus to become the hub of Samsung Bioepis’ drive for accelerated development of next-gen biologic medicines.
Biogen and Apple partner on cognitive health study pharmatimes
January 13, 2021
Biogen and Apple have announced that they will collaborate on a new virtual research study investigating the role of smart devices could have on monitoring cognitive health.
Biogen Licenses CEVEC AAV Mfg. Technology contractpharma
January 11, 2021
Biogen gains rights to ELEVECTA Technology for manufacturing of gene therapy products.
EU authorises intramuscular administration of Biogen’s Plegridy for MS pharmatimes
January 07, 2021
A new intramuscular (IM) injection option of Biogen’s Plegridy (peginterferon beta-1a) has been approved by the European Commission for the treatment of relapsing-remitting multiple sclerosis (MS).
Biogen, ViGeneron Enter Gene Therapy Collaboration contractpharma
January 07, 2021
ViGeneron GmbH has announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases.
Biogen applies for approval of Alzheimer’s drug, aducanumab in Japan expresspharma
December 11, 2020
Biogen said it has filed for regulatory approval in Japan for an Alzheimer’s disease drug it developed with local partner Eisai.
Samsung Bioepis, Biogen Announce FDA Filing Acceptance of Lucentis Biosimilar americanpharmaceuticalreview
December 04, 2020
Samsung Bioepis and Biogen announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for SB11, a proposed biosimilar referencing Lucentis® (ranibizumab).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page